Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals

BACKGROUND: During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Lagler, Heimo, Grabmeier-Pfistershammer, Katharina, Touzeau-Römer, Veronique, Tobudic, Selma, Ramharter, Michael, Wenisch, Judith, Gualdoni, Guido Andrés, Redlberger-Fritz, Monika, Popow-Kraupp, Theresia, Rieger, Armin, Burgmann, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357418/
https://www.ncbi.nlm.nih.gov/pubmed/22629330
http://dx.doi.org/10.1371/journal.pone.0036773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357418/
https://www.ncbi.nlm.nih.gov/pubmed/22629330
http://dx.doi.org/10.1371/journal.pone.0036773

Ejemplares similares